SCHEMBL2477690

SCHEMBL2477690

COc1ccc(S(=O)(=O)Nc2ccccc2C(=O)O)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.70
ALDH1A1 P00352 3/20 0.70
TP53 P04637 1/20 0.70
HPGD P15428 1/20 0.70
HTT P42858 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
KMT2A Q03164 6/20 0.67
MEN1 O00255 5/20 0.67
KEAP1 Q14145 3/20 0.65
KCNA5 P22460 1/20 0.64
KDM4E B2RXH2 2/20 0.63
NFE2L2 Q16236 2/20 0.62
SQSTM1 Q13501 1/20 0.62
GAA P10253 3/20 0.61
POLB P06746 1/20 0.60
SLC16A3 O15427 1/20 0.60
TUBB4A P04350 1/20 0.59
TUBB P07437 1/20 0.59
TUBA3C P0DPH7 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30486834 1.00 LMNA (0.70) LMNAALDH1A1TP53HPGDHTT
SCHEMBL5158052 0.89 LMNA (0.79) LMNAALDH1A1TP53HPGDHTT
SCHEMBL4801356 0.87 LMNA (0.69) LMNAALDH1A1TP53HPGDHTT
SCHEMBL3559360 0.86 LMNA (0.61) LMNAALDH1A1TP53HPGDHTT
SCHEMBL7213042 0.85 LMNA (0.69) LMNAALDH1A1TP53HPGDHTT
SCHEMBL23200342 0.85 MEN1 (0.66) LMNAALDH1A1TP53KMT2AMEN1
SCHEMBL7313843 0.85 ALDH1A1 (0.60) LMNAALDH1A1TP53HPGDHTT
SCHEMBL1466906 0.85 ALDH1A1 (0.72) LMNAALDH1A1HPGDKMT2AMEN1
SCHEMBL12768028 0.85 KEAP1 (0.81) LMNAALDH1A1TP53HPGDHTT
SCHEMBL3551774 0.84 LMNA (0.58) LMNAALDH1A1TP53HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116375611-A Method for synthesizing difluoroalkyl compound from fatty amine 浙江工业大学 2023-07-04 CN disclosed
EP-2935234-A1 ENZYME INHIBITORS University of Sunderland (GB) 2015-10-28 EP disclosed
WO-2014096864-A9 ENZYME INHIBITORS UNIVERSITY OF SUNDERLAND (GB) 2015-03-05 WO disclosed
WO-2014096864-A1 ENZYME INHIBITORS UNIVERSITY OF SUNDERLAND (GB) 2014-06-26 WO disclosed
EP-1385820-B1 ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2011-10-12 EP disclosed
EP-1385820-B1 ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2011-10-12 EP disclosed
CN-100522937-C Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof AVENTIS PHARMA GMBH (DE) 2009-08-05 CN disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
CN-1522244-A Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof ������ҽҩ�¹����޹�˾ 2004-08-18 CN disclosed
EP-1385820-A1 ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF Sanofi-Aventis Deutschland GmbH (DE) 2004-02-04 EP disclosed
US-20030187033-A1 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-10-02 US disclosed
WO-2002088073-A1 ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE KCNH1, KCNH2, KCNJ2 LMNA 981/4885ALDH1A1 1053/4885TP53 4806/4885
US-20030187033-A1 Anthranilamides and methods of their use KCNH1, KCNJ2, KCNH2 LMNA 1186/4885ALDH1A1 934/4885TP53 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.